United States · FDA National Drug Code directory
PANCREAZE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 62541-406_36e934b1-3fbb-8f0c-e063-6294a90a968c
- Product NDC
- 62541-406
- Form
- CAPSULE, DELAYED RELEASE
- Composition / generic term
- PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE
- Labeler
- VIVUS LLC
- Marketing category
- BLA
- Marketing start / end (source format)
- 20210701
- Source listing expiry
- 20261231
Source-listed ingredients
- PANCRELIPASE LIPASE — 37000 [USP'U]/1
- PANCRELIPASE AMYLASE — 149900 [USP'U]/1
- PANCRELIPASE PROTEASE — 97300 [USP'U]/1
These values do not establish equivalence or a dose recommendation.
Packages
- 2 BOTTLE, GLASS in 1 CARTON (62541-406-10) / 50 CAPSULE, DELAYED RELEASE in 1 BOTTLE, GLASS (62541-406-50) · 62541-406-10
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →